U.S. markets open in 2 hours 1 minute
  • S&P Futures

    4,273.00
    -34.75 (-0.81%)
     
  • Dow Futures

    33,910.00
    -208.00 (-0.61%)
     
  • Nasdaq Futures

    13,532.00
    -126.25 (-0.92%)
     
  • Russell 2000 Futures

    2,005.80
    -17.50 (-0.86%)
     
  • Crude Oil

    86.33
    -0.20 (-0.23%)
     
  • Gold

    1,782.90
    -6.80 (-0.38%)
     
  • Silver

    19.75
    -0.33 (-1.64%)
     
  • EUR/USD

    1.0164
    -0.0007 (-0.07%)
     
  • 10-Yr Bond

    2.8240
    0.0000 (0.00%)
     
  • Vix

    20.38
    +0.43 (+2.16%)
     
  • GBP/USD

    1.2076
    -0.0018 (-0.15%)
     
  • USD/JPY

    135.1620
    +0.9470 (+0.71%)
     
  • BTC-USD

    23,801.31
    -293.34 (-1.22%)
     
  • CMC Crypto 200

    567.09
    -4.83 (-0.84%)
     
  • FTSE 100

    7,508.11
    -27.95 (-0.37%)
     
  • Nikkei 225

    29,222.77
    +353.86 (+1.23%)
     

UPDATE 1-Bavarian Nordic raises outlook for third time buoyed by U.S. vaccine order

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

(Adds detail, CEO comment, background)

COPENHAGEN, June 10 (Reuters) - Bavarian Nordic raised its financial guidance for 2022 for the third time in a month on Friday after receiving a large order for its monkeypox vaccine by the U.S. Biomedical Advanced Research and Development Authority (BARDA).

The order by BARDA for the company's smallpox vaccine, which has been approved against monkeypox in Canada and the United States, where it is branded Jynneos, is for 500,000 doses for delivery later this year.

"The long-term commitment from the U.S. government to the development and procurement of JYNNEOS has provided the opportunity to act swiftly, ensuring a rapid deployment of vaccines to mitigate the current monkeypox outbreak," CEO Paul Chaplin said in a statement.

The company said the total U.S. inventory of the vaccine would reach nearly two million doses when combined with a 2020 order for 1.4 million doses.

In recent weeks Bavarian has announced several deals with undisclosed countries for the supply of its monkeypox vaccine, prompting two upgrades to its financial guidance for this year.

The vaccine developer, which also produces a vaccine against the Ebola disease, said interest from countries around the world has been "overwhelming".

The company now expects annual revenue in the range of 1.8 billion to 2.0 billion Danish crowns ($256 million to $285 million), up from a previous projection of 1.4 billion to 1.6 billion crowns.

It expects an EBITDA loss of between 700 million and 900 million crowns, against an earlier estimated loss of between 900 million and 1.1 billion crowns.

($1 = 7.0165 Danish crowns) (Reporting by Nikolaj Skydsgaard; editing by David Goodman and Jason Neely)